Announcement - To visit The Association of Physicians of India – Tamilnadu State Chapter –Click Here.
We are pleased to announce the MIDTAPICON Clinical Edge 2026 – More details
Announcement - To visit The Association of Physicians of India – Tamilnadu State Chapter –Click Here.
We are pleased to announce the MIDTAPICON Clinical Edge 2026 – More details
Announcement - To visit The Association of Physicians of India – Tamilnadu State Chapter –Click Here.
We are pleased to announce the MIDTAPICON Clinical Edge 2026 – More details
Volume 2, Issue 3, Pages 1-4
Insulin resistance (IR) is a key underlying pathophysiology in type 2 diabetes mellitus (T2DM). Thiazolidinediones (TZDs) are oral antidiabetic drugs (OADs) that can address IR. However, their use has been limited due to the associated adverse effects. A novel TZD – Lobeglitazone – has been introduced, which is a dual agonist of peroxisome proliferator-activated receptor (PPAR) and has been reported to have a favorable safety and efficacy profile. This paper summarizes some key characteristics of this agent and the findings from two recent studies conducted in Korea and India.
Type 2 diabetes mellitus, Lobeglitazone, insulin resistance.
This work is licensed under the Creative Commons Attribution 4.0 International License.